RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:scRNA-seq reveals an immune microenvironment and JUN-mediated NK cell exhaustion in relapsed T-ALL.
scRNA-seq reveals an immune microenvironment and JUN-mediated NK cell exhaustion in relapsed T-ALL.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
T细胞急性淋巴细胞白血病(T-ALL)是一种以高复发率为特征的异质性疾病。通过单细胞转录组分析,我们刻画了T-ALL患者骨髓免疫微环境的特征,鉴定出13个主要细胞簇。这些患者表现出异常扩增的造血干细胞(HSCs)和粒-单核祖细胞(GMPs),以及CD4+ T细胞、CD8+ T细胞和自然杀伤(NK)细胞中的免疫抑制特征。对CD4+ T细胞进行细分,揭示了两个在T辅助(Th)1/Th2之间过渡的亚群,即Annexin-A1(ANXA1)- GATA3 - CD4+ T和ANXA1 + GATA3 + CD4+ T。
此外,NK细胞在复发T-ALL患者的肿瘤微环境中表现出耗竭,JUN被鉴定为关键因子。此外,JUN在T-ALL中也高表达,并且对其维持增殖至关重要。JUN抑制剂对白血病细胞表现出成功的致死作用,并改善了复发T-ALL细胞系中的NK细胞耗竭,以及在细胞源性肿瘤异种移植(CDX)、患者源性肿瘤异种移植(PDX)和NOTCH1突变小鼠模型中也是如此。
总之,我们的发现增进了对T-ALL复发机制的理解,并支持为复发T-ALL患者开发创新的免疫疗法。
T cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous disease characterized by a high relapse rate. By single-cell transcriptome analysis, we characterize the bone marrow immune microenvironment in patients with T-ALL, identifying 13 major cell clusters.
These patients exhibited abnormally expanded hematopoietic stem cells (HSCs) and granulocyte-monocyte progenitors (GMPs), immunosuppressive traits in CD4 + T, CD8 + T, and natural killer (NK) cells. Subdividing CD4 + T cells reveal two subsets transitioning between T helper (Th)1/Th2, Annexin-A1 (ANXA1) - GATA3 - CD4 + T, and ANXA1 + GATA3 + CD4 + T.
Additionally, NK cells demonstrate exhaustion in the tumor microenvironment of patients with relapsed T-ALL, with JUN identified as a critical factor.
Additionally, JUN is also highly expressed in T-ALL and is crucial for maintaining its proliferation. The JUN inhibitor exhibited successful lethality toward leukemia cells and ameliorated NK cell exhaustion in relapsed T-ALL cell line, as well as in cell-derived tumor xenograft (CDX), patient-derived tumor xenograft (PDX), and NOTCH1-mutant mouse models. In summary, our findings enhance the understanding of T-ALL relapse mechanisms and support the development of innovative immunotherapies for patients with relapsed T-ALL.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。